MX2020010667A - Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos. - Google Patents
Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos.Info
- Publication number
- MX2020010667A MX2020010667A MX2020010667A MX2020010667A MX2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A MX 2020010667 A MX2020010667 A MX 2020010667A
- Authority
- MX
- Mexico
- Prior art keywords
- imbalanced
- prodrugs
- nucleotides
- treatment
- deoxynucleoside
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656861P | 2018-04-12 | 2018-04-12 | |
| PCT/US2019/027364 WO2019200340A1 (en) | 2018-04-12 | 2019-04-12 | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010667A true MX2020010667A (es) | 2021-01-08 |
Family
ID=68163825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010667A MX2020010667A (es) | 2018-04-12 | 2019-04-12 | Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11628182B2 (https=) |
| EP (1) | EP3773603A4 (https=) |
| JP (2) | JP7620781B2 (https=) |
| CN (1) | CN112384228A (https=) |
| AU (2) | AU2019253023B2 (https=) |
| BR (1) | BR112020020804A2 (https=) |
| CA (1) | CA3096264A1 (https=) |
| IL (1) | IL277725B2 (https=) |
| MX (1) | MX2020010667A (https=) |
| WO (1) | WO2019200340A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3096264A1 (en) | 2018-04-12 | 2019-10-17 | Modis Therapeutics Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| WO2022204555A1 (en) * | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| US20230000890A1 (en) * | 2021-06-18 | 2023-01-05 | Zogenix Mds, Inc. | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| WO1995026971A1 (en) | 1994-03-31 | 1995-10-12 | Nippon Shinyaku Co., Ltd. | Cyclic nucleotide derivative |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| US10292996B2 (en) * | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| LT3505174T (lt) | 2015-06-17 | 2020-09-10 | The Trustees Of Columbia University In The City Of New York | Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus |
| CA3005444A1 (en) * | 2015-11-16 | 2017-05-26 | Ichorion Therapeutics, Inc. | Nucleic acid prodrugs |
| KR20190057277A (ko) * | 2016-06-24 | 2019-05-28 | 에모리 유니버시티 | B형 간염 바이러스 치료용 포스포아미데이트 |
| CA3096264A1 (en) | 2018-04-12 | 2019-10-17 | Modis Therapeutics Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
-
2019
- 2019-04-12 CA CA3096264A patent/CA3096264A1/en active Pending
- 2019-04-12 JP JP2020556284A patent/JP7620781B2/ja active Active
- 2019-04-12 AU AU2019253023A patent/AU2019253023B2/en active Active
- 2019-04-12 WO PCT/US2019/027364 patent/WO2019200340A1/en not_active Ceased
- 2019-04-12 US US17/046,865 patent/US11628182B2/en active Active
- 2019-04-12 CN CN201980038898.2A patent/CN112384228A/zh active Pending
- 2019-04-12 MX MX2020010667A patent/MX2020010667A/es unknown
- 2019-04-12 BR BR112020020804-3A patent/BR112020020804A2/pt unknown
- 2019-04-12 EP EP19784627.2A patent/EP3773603A4/en active Pending
- 2019-04-12 IL IL277725A patent/IL277725B2/en unknown
-
2023
- 2023-02-10 US US18/167,308 patent/US12419901B2/en active Active
- 2023-02-10 US US18/167,317 patent/US20230181617A1/en active Pending
- 2023-12-21 JP JP2023215758A patent/JP7784411B2/ja active Active
-
2025
- 2025-03-14 AU AU2025201857A patent/AU2025201857A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277725B2 (en) | 2024-02-01 |
| JP2024038011A (ja) | 2024-03-19 |
| AU2019253023A1 (en) | 2020-11-12 |
| EP3773603A1 (en) | 2021-02-17 |
| EP3773603A4 (en) | 2022-03-30 |
| IL277725A (en) | 2020-11-30 |
| BR112020020804A2 (pt) | 2021-01-12 |
| US20210077519A1 (en) | 2021-03-18 |
| JP2021521210A (ja) | 2021-08-26 |
| JP7620781B2 (ja) | 2025-01-24 |
| US11628182B2 (en) | 2023-04-18 |
| JP7784411B2 (ja) | 2025-12-11 |
| IL277725B1 (en) | 2023-10-01 |
| US12419901B2 (en) | 2025-09-23 |
| CA3096264A1 (en) | 2019-10-17 |
| US20230181617A1 (en) | 2023-06-15 |
| AU2025201857A1 (en) | 2025-04-03 |
| CN112384228A (zh) | 2021-02-19 |
| WO2019200340A1 (en) | 2019-10-17 |
| US20230181616A1 (en) | 2023-06-15 |
| AU2019253023B2 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| CL2021001228A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| CO2021006672A2 (es) | Moduladores de nlrp3 | |
| CL2019003270A1 (es) | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. | |
| EA201692537A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| MX2018003161A (es) | Metodos para tratar infecciones por virus arenaviridae y coronaviridae. | |
| MX2018016331A (es) | Formas cristalinas de compuesto de triazolopirimidina. | |
| MX378299B (es) | Metodos para tratar infecciones por el virus de filoviridae. | |
| CO2017006962A2 (es) | Derivados de 2-anilinopirimidina sustituida como moudladores de egfr | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| MX385138B (es) | Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes. | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
| CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| CL2017000312A1 (es) | Elección de microarn como diana para trastornos metabólicos | |
| UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| CO2017010530A2 (es) | Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos | |
| MX2020010667A (es) | Profarmacos de desoxinucleosidos para el tratamiento de enfermedades causadas por reservas desequilibradas de nucleotidos. |